Background. Human immunodeficiency virus (HIV)-seropositive men who have sex with men (MSM) are at risk for anal intraepithelial neoplasia (AIN) and cancer. The goal of this study was to identify risk factors associated with high-grade AIN (AIN-2,3) in HIV-positive MSM, including the receipt of highly active antiretroviral therapy (HAART).
Human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) are at increased risk for anal intraepithelial neoplasia (AIN) and cancer [1] [2] [3] . High-grade AIN (AIN-2,3) is the immediate precursor to anal cancer [4] . Although human papillomavirus (HPV) is the etiologic agent of these diseases, HPV infection is almost universal in HIV-seropositive MSM [5] [6] [7] . Factors predictive of AIN-2,3 would be useful to identify HIV-seropositive MSM who are at higher risk for disease. HPV types 16, 18, or 31; infections due to multiple types; and low blood CD41 cell counts have been associated with AIN-2,3 [5, 6, [8] [9] [10] [11] .
Highly active antiretroviral therapy (HAART) against HIV decreased the rate of AIDS-related opportunistic infections and neoplasia [12, 13] . In contrast to most AIDS-defining cancers, the incidence of anal cancer is increasing since the advent of HAART [14, 15] . The reasons underlying this trend are still unknown. Data on the prospective risk of AIN in HIV-seropositive MSM were mostly obtained in the pre-HAART era. The main identified risk factors for progression to AIN-2,3 include anal HPV16 or 18 infection, multiple HPV type infections, and blood CD41 cell counts in some but not all studies [2, [16] [17] [18] . Only a few small crosssectional studies and 1 prospective study performed over a 6-month period in a cohort of patients receiving HAART, have yielded equivocal results regarding the benefits of HAART in reducing the prevalence of AIN [19] [20] [21] [22] [23] .
To more comprehensively study the effects of HAART on the risk of high-grade AIN (AIN-2,3), we conducted a longitudinal study on the natural history of HPV infection and AIN in a cohort of HIV-seropositive MSM. We assessed the value of several factors to predict development of AIN-2,3 in the context of duration of and response to HAART.
MATERIALS AND METHODS

Study Design and Population
Participants in the Human Immunodeficiency and Papilloma Virus Research Group (HIPVIRG) cohort were enrolled from January 2002 through January 2005. All participants gave written informed consent, and the study was approved by institutional review boards at all sites. The study protocol has been described previously [11] . Briefly, men 18 to 65 years of age with a history of sexual intercourse with men who were receiving HAART (n 5 221) or expected to be treated with HAART within the next 6 months (n 5 26) were recruited. Men who were receiving HAART had been treated for a median of 659 days at inclusion: 28 for <6 months [median duration, 55 days], 99 for .6 months [median duration, 945 days]) with virological suppression of HIV (plasma HIV RNA level ,50 copies/mL) at baseline, (94 for .6 months [median duration, 661 days]) but with virological failure (plasma HIV RNA level >50 copies/mL) at study entry. HAART regimens included those with (1) >2 nucleotide reversetranscriptase inhibitors (NRTIs) with >1 protease inhibitor (PI) or .1 nonnucleoside reverse-transcriptase inhibitor (NNRTI); (2) 1 NRTI with >1 PI and >1 NNRTI; or (3) a quadruple NRTI combination of abacavir-lamivudine-zidovudine-tenofovir [24] . All other participants were considered to be using a non-HAART regimen. Anti-HIV treatment was assessed at each visit by a questionnaire administered by the research nurse.
Data Collection, Anal Cytology, and HPV Testing Participants were evaluated every 6 months for 3 years with a self-administered questionnaire and determination of current CD41 cell counts and plasma HIV RNA loads, as reported elsewhere [11] . Nadir CD41 cell counts and plasma HIV RNA loads at the beginning of current HAART were retrieved from medical charts. Two Dacron swabs were consecutively inserted in the anal canal for cytological analysis and HPV testing [11] . The second swab sample was rinsed in 1.5 mL of PreservCyt (Cytyc) and was processed with Master pure (Epicentre) for DNA extraction [7] . The integrity of sample DNA was assessed by amplification of ß-globin [7] . ß-globin-positive samples were amplified for HPV DNA with PGMY primers and genotyped with the reverse Line-blot detection assay for 36 genital types, as previously described [11] .
High-resolution Anoscopy
High-resolution anoscopy (HRA) was performed at baseline and repeated yearly thereafter for those without AIN or with AIN-1 and was repeated every 6 months for individuals with AIN-2,3, if not treated. Aceto-white areas were biopsied and processed for routine histopathological examination. Histological slides were reviewed by 2 pathologists and graded using the criteria routinely used for cervical intraepithelial neoplasia (CIN) into normal, AIN-1, AIN-2, AIN-3, or carcinoma in situ. The anal mucosa devoid of an aceto-white lesion was not biopsied for 28 participants and was considered ''normal.'' Four participants with classical exophytic condylomas at the accrual HRA never had a biopsy of these condylomas during the study period and were considered to have AIN-1. One subject was not considered in our analyses because AIN-2,3 was suspected at the first HRA, but the biopsy specimen was too small for interpretation, and the patient never returned for a second HRA.
Statistical Analysis
The outcome of interest was the histological diagnosis of AIN-2,3 on biopsy specimens obtained during HRA. If multiple biopsies were available at the same visit, the highest grade was used to denote the lesion status at that visit. The frequency distributions of AIN and the findings of cytological analysis at each visit were calculated as simple proportions based on the actual numbers of subjects evaluated. The progression rate and cumulative risks were calculated using actuarial analysis. We constructed Kaplan-Meier curves that portrayed the cumulative high-grade lesion history, including prevalent findings at baseline, stratified by baseline characteristics. HPV genotypes that we considered to be high risk were as follows: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 82. Cox proportional hazards regression analyses were performed to identify potential predictors among baseline variables. For the period prevalence logistic regression, we retained the worst value reached by a subject for the following variables until the event: absolute CD41 cell count and HPV infection. Baseline results were used for other variables, including age, smoking status, number of sexual partner within the previous year, duration of current HAART regimen, CD41 cell count before initiation of current HAART regimen. To examine the mediating effect of HPV for the other variables, a multivariate period prevalence logistic regression was first performed through stepwise forward regression (P 5 .10 for entry; P 5 .15 for removal) using all variables (except HPV) with AIN-2,3 as the outcome. We then fitted separate logistic regression models, including all of the independent predictors obtained by stepwise regression, with and without HPV infection indicators, to examine the extent of the mediating effect. We fitted period prevalence logistic regression to identify factors associated with cumulative risk of AIN-2,3 to account for cases that may have been prevalent and missed at the first(s) visit. Statistical analyses were performed with Stata software, version 11.0 (Stata).
RESULTS
Study Population and Anal Dysplasia Prevalence
The characteristics of the 247 participants at study inclusion have been described previously [7, 11] . At study entry, the median age of participants was 43 years (range, 21-66 years), 38% were current smokers, 90% were receiving HAART, the median CD41 cell count was 380 cells/mL (range, 0-1440 cells/mL), and 56% of subjects had an undetectable HIV load. The current analysis includes a total of 8014 person-months of follow-up, with a median follow-up time of 38 months. The characteristics of subjects with .5 follow-up visits were similar to those of the whole cohort at baseline [11] . On further examination, however, the early loss to follow-up was slightly differential on the baseline HRA results, as follows: of the participants with normal findings or AIN-1 at baseline, 13% (22 of 171) were lost to follow-up within the first year, compared with 9% (7 of 75) among the other subjects (P 5 .52). Table 1 shows the distribution of anal cytology and HRA findings by yearly visits. Cumulatively, 46% of the subjects had low-grade squamous intraepithelial lesions as the highest grade of abnormal cytological findings, 17% had high-grade squamous intraepithelial lesions at least once, and only 11% had normal cytological findings throughout the study. Also cumulatively, only 7% of men had normal HRA findings throughout the complete follow-up period. AIN-2,3 or worse was identified in 54% (132 of 246) of the participants at least once.
Two participants (1%) experienced progression to invasive anal cancer. One 40-year-old participant was a current smoker. His CD41 cell count, which was 130 cells/mL before HAART, increased to 410 cells/mL while receiving HAART. HIV load was undetectable for the first 3 visits, increased to .5000 copies/mL during the fourth and fifth visits, and was undetectable at the last visit. HPV16 was detected persistently. AIN-2 was detected at recruitment, but only AIN-1 was detected on subsequent HRA. A small-cell carcinoma was detected at a different site from that of the initial AIN-2 at the last visit. Another participant was a 50-year-old former smoker. His CD41 cell count was 50 cells/mL before HAART and increased to 240 cells/mL during follow-up.
The HIV load was .5000 copies/mL for the first 4 visits and became undetectable thereafter. HPV26, 31, 45, 53, 82, and 54 were detected persistently. AIN-3 over the entire transformation zone was demonstrated at each visit and could not be treated. Both participants had been receiving their current HAART regimen for ,2 years.
Progression to AIN-2,3
Of the 172 participants without AIN-2,3 at baseline, 25 men were lost to follow-up for HRA, leaving 147 participants for whom we could calculate a rate of progression. In these participants, 57 had incident AIN-2,3 in 4467 person-months of follow-up, resulting in a progression rate of 12. Figures 1 and 2 depict the Kaplan-Meier curves of detection of AIN-2,3 according to cytological analysis and HPV test results at baseline, respectively. The differences in cumulative rates were significant in both analyses (P , .001, log-rank test). Of the 15 participants with high-grade squamous intraepithelial lesions at baseline, 14 had AIN-2,3 confirmed by HRA at the same visit, and AIN-2,3 was found at the third visit for the remaining participant. For men with low-grade squamous intraepithelial lesions, atypical squamous cells of undetermined significance, or normal cytological findings, we detected AIN-2,3 in 54% (95% CI, 42%-68%), 44% (95% CI, 34%-57%) and 29% (95% CI, 20%-40%) of the patients within 2 years and in 70% (95% CI, 58%-82%), 53% (95% CI, 42%-65%) and 40% (95% CI, 29%-52%) of them within 3 years, respectively. Regarding HPV testing, 64% (95% CI, 53%-74%) of subjects infected with HPV-16 at baseline developed AIN-2,3 by 2 years versus 40% (95% CI, 31%-49%) of those with high-risk HPV types other than 16 and 7% (95% CI, 2%-26%) of men with low-risk HPV types only or no HPV DNA. Three men who were not infected with a high-risk HPV type at baseline developed AIN-2,3. Two of them had a high-risk genotype identified during follow-up, and one of these patients had results that were persistently positive for HPV53, which is a possibly oncogenic type [25] .
Age-Adjusted Analysis of Risk Factors Table 2 depicts the results of age-adjusted Cox regression and period prevalence logistic regression for AIN-2,3 (incident only for Cox analysis and prevalent and incident cases combined for the logistic regression). Men with CD41 cell counts ,50 cells/mL before initiation of their current HAART were at increased risk for AIN-2,3 when compared with men with CD41 cell counts .350 cells/mL in Cox regression but not in the period prevalence logistic regression, despite a comparable magnitude of the effect. Having .10 sexual partners within the last year and infection with a high-risk HPV genotype, especially HPV16 or HPV18, were cumulatively significant risk factors for AIN-2,3. Infection with one of the alpha species 5 (HPV26, 51, 69, and 82) or 9 (HPV16, 31, 33, 35, 52, 58, and 67) genotypes also increased the risk for AIN-2,3, which is an effect mainly driven by HPV16 and HPV26 (data not shown).
Multivariate Period Prevalence Logistic Regression for AIN-2,3 Table 3 presents independent predictors of AIN-2,3 with and without adjustment for HPV infection. Men 40-49 years of age a Represents the highest grade reached for each subject during study follow-up, with invalid smears being discarded. Cumulative numbers exceed the total visits because cytological examination was performed every 6 months, as was anoscopic examination if AIN-2,3 was identified.
b One of the cancer cases was discovered at 30 months and censored afterwards, but we added him here on the table for clarity. NOTE. The results of age-adjusted Cox regression and period prevalence logistic regression for AIN-2,3 (incident only for Cox analysis and prevalent and incident combined for the logistic regression) are shown. The latter was also adjusted for the number of visits to control for lesion-detection opportunity. All variables are determined before ascertaining the outcome. AIN, anal intraepithelial neoplasia; CI, confidence intervals; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, high risk; N, numbers; NA, not applicable; ND, not determined; subj., subjects; OR, odds ratio; ref, reference.
a Age is adjusted for the no. of visits only.
b The baseline absolute CD41 cell count was used for the Cox analysis. The lowest CD41 cell count result obtained within the study until reaching the outcome (AIN 2/3) was used for the period prevalence logistic regression.
c Having the stated type or one of the stated groups at baseline for the Cox analysis, adjusted for age. Having the stated type or one of the stated groups at least once at any visit up until the detection of the outcome (AIN 2/3), adjusted for age and the number of visits for the period prevalence logistic regression. Reference categories include those without the stated infection status. e Numbers in each category do not always add-up to the total because of missing data.
f Adjusted for age and the no. of visits.
had 3 times the risk of AIN-2,3 than did men ,40 years of age. When adjusting for HPV infection, men .50 years of age had an even higher risk, which was almost five fold that of men ,40 years of age. Men whose CD41 cell counts were ,50 cells/mL before beginning HAART had a 12-to 14-fold increased risk of having AIN-2,3, compared with men whose CD41 cell counts were .50 cells/mL, with the point estimate even increasing after adjustment for HPV infection. This effect is thus independent of HPV infection. Men who had received their current HAART regimen for 4 years or more had a lower risk of AIN-2,3, when compared with that for men not receiving HAART or who had been receiving their current HAART regimen for ,4 years. The significance was lost after adjusting for HPV infection, but the point estimate remained very low and relatively unchanged, thus suggesting that at least some of the effect is independent of HPV infection. Anal infection by HPV16 or HPV18 was associated with a 14-fold increased risk of AIN-2,3. When both types were detected at least once, the risk was 31-fold higher than that for men who had never acquired HPV16 or 18. Adjustments for current CD41 cell count, time since HIV infection diagnosis, and HIV load were not retained in the model because of a lack of significance, and they did not influence the point estimates of the other variables.
DISCUSSION
In our cohort of HIV-seropositive MSM, the cumulative incidence of AIN-2,3 over a 3-year period reached 37%, which was similar to a rate of incident AIN-2,3 of 34% over a 4-year period in another cohort [2] . Collectively, these results confirm the relevance of screening for AIN-2,3 in HIV-seropositive MSM.
Our findings also underscore the importance of HPV typing, as well as sexual and HIV history, as predictive factors for AIN-2,3. To our knowledge, this is the first report of the rate of incident AIN-2,3 in HIV-infected MSM in the HAART era. Newly detected cases, however, likely included participants who were not true incident cases. Some cases of AIN-2,3 may not have been detected on the first HRA, resulting in an underestimation of the baseline prevalence and an overestimation of the incidence of AIN-2,3. To minimize the effect of misclassification by initial HRA, incident AIN-2,3 was calculated for MSM with 2 negative HRA results on their first 2 visits. However, this more stringent definition of normality at inclusion could have excluded the more aggressive lesions and over-represented cases with a longer time to disease onset. Because incident cases that were detected in the first follow-up visits could have been missed prevalent cases, we preferred an approach that used period prevalence logistic regression rather than multivariate analysis.
Response to HAART has resulted in lower rates of opportunistic infection for many agents but has not resulted in lower prevalence of HPV-induced lesions [15, 23] . The prolonged survival of HIV-seropositive individuals with reduced immunocompetence who receive treatment could, paradoxically, provide adequate time for progression to invasive cancer before the death of the patient [19, 26, 27] . Palefsky et al [22] has previously shown that the HAART-induced increase in CD41 cell counts does not necessarily correspond to greater protection against AIN. In these studies, prolonged use of HAART had no impact on the history of AIN [19, 22] . A cross-sectional study reported a protective effect from HAART that was only identified when adjusting for nadir CD41 cell counts [21] . We also found that men who had received their current HAART regimen for a longer time had a lower risk of AIN-2,3, especially after adjusting for nadir CD41 cell counts. This suggests that, although one cannot fully recover from HIV-induced immune deficiency, HAART could have some beneficial effect in reducing the risk of AIN-2,3. Nevertheless, the incidence of AIN-2,3 in our cohort is the same as that reported in the pre-HAART era [2] . If HAART was truly protective, anal cancer incidence would be decreasing, in contrast to current reports [14, 15] . With a high incidence, as observed here, we could expect a higher prevalence than what we observed at accrual. Regression of small AIN-2,3 lesions in men who are receiving HAART could, in part, explain this discrepancy. Because treatment was offered to men with AIN-2,3, we cannot verify this hypothesis. Regression of extensive untreated AIN-2,3 was not encountered here (data not shown). It is also possible that the slightly protective effect of HAART occurs only in the early years of treatment. We studied only the duration of the current HAART regimen and not the lifetime duration of HAART. Thus, HAART could be beneficial for subjects with a good and stable response to HAART. The point estimate of duration of HAART was much lower in the period prevalence logistic regression analysis, which included prevalent cases, than it was in the Cox analysis of incident cases. This could be related to the smaller number of incident cases. It could also support the hypothesis of the effect being mostly on the persistence of AIN-2,3 lesions and not on incident lesions. Studies from the pre-HAART era found associations between lower CD41 cell counts and AIN [2, 17, 28] . Some but not all studies reported an association between lower CD41 cell counts and AIN in individuals receiving HAART [21, 22] . We did not find that lower current CD41 cell counts were predictors of AIN-2,3. Nadir CD41 cell count is one of the best predictors of progression to AIDS-related cancers in HIV-infected populations [14, 29, 30] . Other investigators have reported that nadir CD41 cell counts were independently associated with AIN [21] . In our study, having a CD41 cell count ,50 cells/mL before beginning HAART was an independent predictor of AIN-2,3, suggesting that, although there is immune reconstitution with effective anti-HIV treatments against some pathogens, immune deficits against HPV persist in individuals who are receiving HAART.
The main limitation of our study was the relatively low number of cohort participants. As mentioned above, men free of disease at baseline could have received a misdiagnosis because of a false-negative HRA result. Misclassification of participants on the basis of HRA results is possible, but HRA is the current gold standard to identify AIN. Although wide-area swab specimens were used instead of biopsy specimens for HPV detection, we have shown that the distribution of HPV types in anal swab specimens and biopsy specimens collected concurrently are not appreciably different [7, 11] .
Although men who receive HAART for .4 years had a lower risk of AIN-2,3, severe dysplasia remains extremely common in men treated for HIV infection, and the increasing incidence of anal cancer remains a threat. Our study confirms the high prevalence and high incidence of AIN-2,3 among HIV-infected MSM, even when they receive HAART. Nadir CD41 cell counts are useful in identifying men who are receiving HAART who are at higher risk of developing AIN and who would, therefore, benefit most from HRA screening. HPV typing could also be useful as an adjunct to cytological examination in primary screening.
